Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Morning El. Texrad involved in 5 presentations this year. The all day presentation is for kidney stones (Stonechecker) and prostate cancer (Prostate Checker) but Texrad has clearly been used in other research areas as we know. If you type Texrad into RNSA search engine details provided of all sessions. Interested to see significant time provided for the kidney stone aspect, this appears to be gaining traction in USA and FDA approval expected in near future.
We sold Stonechecker to ex director Trevor Brown (now IQAI) for £50k with a licensed revenue agreement if product commercially available. This certainly seems likely now and provides further revenue streams going forward.
Admitted to market today. No major sell out not that much of an opportunity exists currently, very quiet and illiquid. Would like to think a few sticky holders waiting for clinical commercialization of Texrad lung and entry of other new products. Chairman been open about staff recruits, data scientist and product managers of new products brought to the market. GLA
Earth. Should we expect a TR1 for the 13 million trade last Thursday?
Recent podcast he suggested that placing involved a number of high net worth individuals and improved quality of shareholders. I'm in neither category but have worked extremely hard for what I have invested here. A little bit of respect for all shareholders, whatever their background, wouldn't go amiss.
Hi El, watched game last night, you boys are unrecognizable from early week's, hope it continues! As for share trades, have never seen anything that big in all my time as a long termer. It's too high to be forward sold of placing shares so where did mms get them from to sell? Mystifying?
Elartu, what do you make of those, they are enormous?!!
Someone's confident!
Agree Botak, wonder who the institution is? If he was my GP I would be very reassured but that's not quite the same skills as CEO or Chairman of public listed company! He seems very relaxed and positive about it all, he even released figures on how sales mechanism operates for Texrad. Never heard that before.
Thanks Elartu. I bought stock this pm at below mid price, marked as a sell. Are we to expect a few mm tricks for a while?
Also interesting to note that the placing includes institutional investors. When approved we can expect to see who they are, expect it to be significant and holdings RNS to follow.
Regulatory approval is certain. All the major shareholders are signed up to raising this level of capital including Tom Charlton who is a respected ex director and holds 25%. I believe we are entering a transformational period for the company and as a long term holder will vote in favour of the board. This is a significant capital raise at minimal discount to drive the strong sales growth which has been alluded to in recent company statements.
As a long term holder, I agree DrRich. In current climate it's a really good price. Also, shares are relatively illiquid hence this isn't for flippers, long term investors hold the sway. Sturge and Charlton stumped up decent wedge to support growth as well. Will read again later but first impression positive.
On 25/4/2018 share price 3.15. Since April the following has been announced,
- New company structure introduced and strategic review to build Feedback into a global medical imaging company,
- 2 year contract announced with Royal Papworth Hospital,
- hugely significant board appointments including Simon Sturge (COO of Merck Pharmaceuticals a global leader in this field), he holds over 7 million shares. Also a new medical director with compelling experience and links in the NHS and wider industry. Senior board members taken salaries/fees as options at 1.85p to keep costs down.
- sales increasing globally (100% growth in first quarter)
- Feedback continues to see new growth in Asia and elsewhere with high calibre distribution agreements in place
-FDA approval sought to develop Texrad as medical device in USA
- and today's announcement of additional widening of customer base including new European jurisdictions with sales of Texrad products.
Additionally we know that CE marked Texrad Lung is being developed for integration into Allied Health scanners in NHS and Europe. Company have confirmed earlier via email to some shareholders that this will occur in 2018.
These are really very significant developments for the company and AI is increasing traction in medical imaging.
Interesting times and lots more news to follow from company in due course.
Morning Botak. More validation of Texrad and now being used by 50+ leading hospitals worldwide. It's when not if that clinical adoption is rolled out.
Brings back memories Botak, beautiful track and one of my favourite singers. Have a great weekend.
Poets Laureate!!
price this morning on very small volumes, buy order in? Where our guru Elartu today, he will have some views on this? GLA
Totally agree and add the NOMAD as well. As an auditor in my previous life I cannot believe the lack of internal controls and auditor negligence in this. Not invested but it's a 1/2 billion company not a set of club accounts!! Lots of people asleep on the watch...
Yes Neon, but average trade size nothing like your figure and the buyers are now out in force so some buyers not deterred. Not a stock to short as can move very quickly and could finish close to level today.
Elartu, late night again!